TEI-2306 is a precursor of glutathione biosynthesis. TEI-2306 possesses a unique anti-HIV-1 activity in both chronically and acutely infected cells, and even for free viruses. TEI-2306 can be used for the study of myocardial ischaemia.

PD 161374 is an inhibitor targeting the HIV-1 nucleocapsid protein NCp7. PD 161374 primarily acts on the early stages of viral replication, inhibiting the completion of reverse transcription without affecting viral entry or later assembly. PD 161374 remains active against HIV-1, HIV-2, SIV, and drug-resistant strains. PD 161374 can be used to study antiretroviral agents.

L-738872 is an orally active HIV-l encoded protease inhibitor. L-738872 inhibits the spread of HIV-1 in infected cells.

CGP-75355 is an inhibitor of HIV-1 protease with IC50 of 26 nM. CGP-75355 is a bis(L-tert-leucine) derivative.

KFA-027 is a HIV-1 inhibitor, with an IC50 of 0.398 nM. KFA-027 inhibits capsid-dependent early steps (reverse transcription, nuclear import, integration) and late-stage aberrant capsid assembly in the HIV-1 replication cycle. KFA-027 can be used for the study of multidrug-resistant HIV-1 infections.

(±)-PM 92131 is a non-nucleoside HIV-1 inhibitor. (±)-PM 92131 has an anti-HIV-1 activity with IC50s of 45.7 and 53.8 μM for HIV-1 RF strain in XTT cytoprotection and syncytium-forming assay, respectively. (±)-PM 92131 can be used for HIV infections research.

Asuptegravir (Compound 1) is an inhibitor of HIV integrase activity. Asuptegravir inhibits HIV in HEK293T cells (EC50 = 1.08 nM). Asuptegravir can be studied in anti-AIDs/HIV research.

(+)-PM 92131 is the active enantiomer of (±)-PM 92131. (+)-PM 92131 is a non-nucleoside HIV-1 inhibitor. (+)-PM 92131 has an anti-HIV-1 activity with EC50s of 0.8 and 0.6 μM for HIV-1 RF strain in XTT cytoprotection and syncytium-forming assay, respectively. (+)-PM 92131 can be used for HIV infections research.

Zintevir is an antisense oligonucleotide that targets HIV-1 integrase.

Zintevir sodium is an antisense oligonucleotide that targets HIV-1 integrase.

Peginterferon alfa-2b (PegIFN a-2b) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG. Peginterferon alfa-2b in decreasing viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C.

Lenacapavir (GS-6207) sodium is a HIV-1 capsid inhibitor. Lenacapavir sodium shows anti-HIV activity with an EC50 of 100 pM in MT-4 cells. Lenacapavir sodium displays a mean EC50 of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs).

GSK-364735 sodium (S/GSK-364735 sodium) is the sodium salt form of GSK-364735 that inhibits 5-lipoxygenase with an IC50 value of 26 μM. 15(S)-HEDE is promising for research of inflammatory disease.

GSK-364735 potassium (S/GSK-364735 potassium) is the potassium salt form of GSK-364735, a local anesthetic that inhibits dopamine reuptake through the dopamine transporter.

Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs). Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM.

CGP 57813 is a peptidomimetic inhibitor of HIV protease that can be encapsulated by nanoparticles composed of poly(D,L-lactic acid) (PLA) and pH-sensitive methacrylic acid copolymers and delivered into the body.

BRN3OMe is a potent HIV-1 reverse transcriptase inhibitor. BRN3OMe has the potential for the research of antiviral agent.

Amprenavir (Agenerase) is a HIV protease inhibitor(Ki=0.6 nM) used to treat HIV infection.

GPS491 (EC50 = 0.47 μM) suppresses expression of the HIV-1 structural protein Gag and alters HIV-1 RNA accumulation, decreasing the abundance of RNAs encoding the structural proteins while increasing levels of viral RNAs encoding the regulatory proteins.

Q308 is a small molecule that silences the latent HIV-1 provirus by inhibiting Tat-mediated gene transcription and selectively downregulates the expression levels of the facilitated chromatin transcription (FACT) complex.Q308 induced the preferential apoptosis in HIV-1 latently infected cells, Q308 may reduce the size of the viral reservoir.

Elunonavir is an azapeptide atazanavir analogs useful for treating HIV infections.

NBD-556 is small molecule mimetic of CD4, NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding.

VTD227 is a small molecule Vpr-targeting HIV-1 inhibitor, directly binds to Vpr with Kd of 8.8 uM, inhibits HIV-1 replication in monocyte-derived macrophages (MDM) with IC50 of 0.78 uM.

TX-1918 (TX1918) is a specific inhibitor of HIV-1 capsid assembly taregting the C-terminal domain of HIV-1 capsid (CA CTD) with IC50 of 3.81 uM, inhibits viral replication (EC50=15.16 μM) and inhibits CA assembly in vitro.

SO-7g is a novel highly active HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI), exhibits moderate to excellent potency against wild-type HIV-1 with EC50 of 5.3 nM.

PAV-206 is a novel potent antiretroviral chemotype that inhibits HIV-1 replication with EC50 of 34 nM in HIV-1-infected MT-2 T cells, and 75 nM in HIV-1-infected peripheral blood mononuclear cells (PBMCs), inhibits HIV-1 replication by interfering with HI

JX-7 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with remarkable inhibitory activity against wild-type HIV-1 (EC50=5 nM) and numerous clinically observed variants in MT-4 cells.

iPAF1C (PAF1C inhibitor) is a first-in-class, specific inhibitor of polymerase-associated factor 1 complex (PAF1C), iPAF1C binds specifically to CTR9 and disrupts of PAF1-CTR9 interaction, enhances HIV-1 latency reversal.

GSK-878 (GSK878) is a highly potent, long-acting inhibitor targeting the HIV-1 capsid with picomolar potency against HIV-1 infection in vitro (EC50=39 pM).

GSK3839919 is a potent, allosteric HIV-1 integrase inhibitor (ALLINI).